Therapies
Read more about Low Dose Naltrexone
About Us
Discover Immune Therapeutics
Investors
Investor data
News
Read the latest news

LDN (low dose naltrexone)

Low Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications, is currently used as an immune modulator.

MENK

OGF/MENK has been shown to halt the growth of the cells and is thought to allow immunological mechanisms (e.g. macrophages, natural killer cells) to accomplish the task of destroying the cancerous cells.

0 21 September 2016

Immune Therapeutics, Inc. Announces Appointments to its Medical and Clinical Advisory Board
ORLANDO, Fla., Sept. 21, 2016 /PRNewswire-USNewswire/ — Immune Therapeutics, Inc., a clinical-stage pharmaceutical company focused on the commercialization and development of the first affordable non-toxic immunodulator for the treatment of inflammatory diseases, immune-related disorders, and cancer, today announces the appointment of two new members to its Medical and Clinical Advisory Board comprised of: Joseph M. Chalil, MD and Mak Jawadekar, Ph.D., join Clifford A. Selsky, Ph.D., MD and Nicholas P. Plotnikoff Ph.D.

Posted in Press Releases by admin
0 23 August 2016

ORLANDO, Fla., Aug. 23, 2016 /PRNewswire-USNewswire/ — Immune Therapeutics, Inc. (OTCQB-IMUN) (“IMUN”), headquartered in Orlando, Florida, is a clinical-stage biopharmaceutical company involved in the commercialization, manufacturing, distribution and marketing of its novel immunotherapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system.

Posted in Press Releases by admin
0 26 July 2016

ORLANDO, FL–(Marketwired – Jul 26, 2016) – Immune Therapeutics, Inc. (OTCQB: IMUN) An Informational Shareholder Meeting will be held on Wednesday, August 17, 2016, at 10 a.m. EDT, at the Citrus Club, 255 South Orange Avenue, Suite 1800, Orlando, FL 32801.

Posted in Press Releases by admin
Load More